BR0113201A - processo para tratar distúrbios neurodegenerativos da retina e da cabeça do nervo óptico - Google Patents

processo para tratar distúrbios neurodegenerativos da retina e da cabeça do nervo óptico

Info

Publication number
BR0113201A
BR0113201A BRPI0113201-6A BR0113201A BR0113201A BR 0113201 A BR0113201 A BR 0113201A BR 0113201 A BR0113201 A BR 0113201A BR 0113201 A BR0113201 A BR 0113201A
Authority
BR
Brazil
Prior art keywords
optic nerve
retina
nerve head
neurodegenerative disorders
treating neurodegenerative
Prior art date
Application number
BRPI0113201-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Daniel A Gamache
Gustav Graff
John M Yanni
Michael A Kapin
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0113201A publication Critical patent/BR0113201A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0113201-6A 2000-08-14 2001-08-13 processo para tratar distúrbios neurodegenerativos da retina e da cabeça do nervo óptico BR0113201A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22513200P 2000-08-14 2000-08-14
PCT/US2001/025319 WO2002013805A2 (en) 2000-08-14 2001-08-13 Method of treating neurodegenerative disorders of the retina and optic nerve head

Publications (1)

Publication Number Publication Date
BR0113201A true BR0113201A (pt) 2006-05-09

Family

ID=22843666

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0113201-6A BR0113201A (pt) 2000-08-14 2001-08-13 processo para tratar distúrbios neurodegenerativos da retina e da cabeça do nervo óptico

Country Status (16)

Country Link
US (1) US6638976B2 (enExample)
EP (1) EP1309322B1 (enExample)
JP (1) JP2004506010A (enExample)
AR (1) AR030346A1 (enExample)
AT (1) ATE330596T1 (enExample)
AU (1) AU8125801A (enExample)
BR (1) BR0113201A (enExample)
CA (1) CA2418059C (enExample)
CY (1) CY1106155T1 (enExample)
DE (1) DE60120990T2 (enExample)
DK (1) DK1309322T3 (enExample)
ES (1) ES2266229T3 (enExample)
MX (1) MXPA03001160A (enExample)
PT (1) PT1309322E (enExample)
TW (1) TWI286933B (enExample)
WO (1) WO2002013805A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132773A1 (en) * 2001-08-13 2004-07-08 Gamache Daniel A Method of treating neurodgenerative disorders of the retina and optic nerve head
WO2004112772A1 (en) * 2003-06-13 2004-12-29 Alcon, Inc. Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
WO2006121963A2 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
SI1906916T1 (sl) * 2005-05-10 2009-02-28 Alcon Inc Oftalmična suspenzija, ki obsega oftalmično zdravilo, poloksamin in glikolno sredstvo za naravnavo toničnosti, uporaba sestavka za pripravo zdravila za zdravljenje oftalmičnih motenj
US8915877B2 (en) 2010-10-12 2014-12-23 Emmett T. Cunningham, JR. Glaucoma drainage device and uses thereof
US9370444B2 (en) 2010-10-12 2016-06-21 Emmett T. Cunningham, JR. Subconjunctival conformer device and uses thereof
RU2458656C1 (ru) * 2011-06-17 2012-08-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения оперированного незакрывшегося макулярного отверстия
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226344A (enExample) 1967-07-31 1971-03-24
SE400966B (sv) 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) * 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) * 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
US4503073A (en) * 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4568695A (en) 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
US4851443A (en) 1985-03-14 1989-07-25 Smith Kline Dauelsberg, Gmbh Carboxylic acid amides, compositions and medical use thereof
DE3668450D1 (de) 1985-03-14 1990-03-01 Smithkline Dauelsberg 5-aminosalicylsaeurederivate von nicht-steroidalen entzuendungshemmenden sauren.
US4683242A (en) 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US4910225A (en) 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5314909A (en) 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
JP3396953B2 (ja) 1994-05-10 2003-04-14 千寿製薬株式会社 網膜疾患予防・治療剤
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5643943A (en) * 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6025353A (en) 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
JP2002534361A (ja) 1999-01-07 2002-10-15 バンダービルト・ユニバーシティ Ｃｏｘ−２選択的阻害剤ではないｃｏｘ阻害化合物から、ｃｏｘ−２選択的阻害剤への変換
US6413965B1 (en) 1999-06-30 2002-07-02 Pfizer Inc. Compositions and treatment for diabetic complications
US6555540B1 (en) 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
US6426341B1 (en) 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device

Also Published As

Publication number Publication date
ES2266229T3 (es) 2007-03-01
WO2002013805A2 (en) 2002-02-21
DE60120990T2 (de) 2007-03-15
CA2418059C (en) 2009-12-22
ATE330596T1 (de) 2006-07-15
EP1309322B1 (en) 2006-06-21
DK1309322T3 (da) 2006-10-23
CA2418059A1 (en) 2002-02-21
WO2002013805A3 (en) 2002-05-30
US20020049255A1 (en) 2002-04-25
JP2004506010A (ja) 2004-02-26
US6638976B2 (en) 2003-10-28
AU8125801A (en) 2002-02-25
PT1309322E (pt) 2006-11-30
MXPA03001160A (es) 2004-08-02
DE60120990D1 (de) 2006-08-03
TWI286933B (en) 2007-09-21
EP1309322A2 (en) 2003-05-14
CY1106155T1 (el) 2011-06-08
HK1057332A1 (en) 2004-04-02
AR030346A1 (es) 2003-08-20

Similar Documents

Publication Publication Date Title
BR0113520A (pt) Processo de preparação de ácidos n-aril-antranìlicos e seus derivados
BR9307077A (pt) Processo para ajuste do formato da córnea de um olho e anel corneal intra-estromático
PT868186E (pt) Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
BR0113776A (pt) Composição de pirrolocarbazóis selecionados fundidos e método para tratar e prevenir várias doenças usando a citada composição
BR9712824A (pt) Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico
ATE319456T1 (de) Verwendung von tetracyclinen zur behandlung von störungen der meibomschen drüsen
PT888325E (pt) Novos amino acidos ciclicos como agentes farmaceuiticos
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
BR0108175A (pt) Derivados de piperazina e piperidina para o tratamento ou a prevenção de danos neuronais
FI970489L (fi) Paikallisesti käytettäviä silmälääkekoostumuksia, jotka sisältävät doksepiinijohdoksia ja soveltuvat allergisten silmäsairauksien hoitoon
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
BR0113201A (pt) processo para tratar distúrbios neurodegenerativos da retina e da cabeça do nervo óptico
WO2001068053A3 (en) Methods and compositions for treating and preventing posterior segment ophthalmic disorders
AU6896801A (en) Use of vegf and homologues to treat neuron disorders
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
BR9707674A (pt) Uso de inibidores de anidrase carbÈnico para tratamento de edema macular.
DE69534620D1 (de) Verfahren zur behandlung von augenerkrankungen
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
MXPA02011921A (es) Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
EP1037622A4 (en) TAURIN DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISORDERS
PT1131073E (pt) Uso de derivados de estaurosporina para o tratamento de doencas oculares neovasculares
WO2002013804A3 (en) Method of treating angiogenesis-related disorders using benzoyl phenylacetic acid
BR9915803A (pt) Composição para o tratamento de neuropatia da retina ou cabeça de nervo ótico, e, processo para tratamento de neuropatia da retina ou cabeça de nervo ótico
BR9713044A (pt) Composto, uso de um composto, processo para sua preparação,e, formulação farmacêutica.
ES2171233T3 (es) Uso de eliprodil para la preparacion de un medicamento para el tratamiento de trastornos isquemicos de la retina o el nervio optico.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]